Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Retina Innovation Showcase


Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that Casey Kopczynski, Ph.D., Chief Scientific Officer presented an overview on Aerie's retina product candidates, at the Ophthalmology Innovation Summit Retina Innovation Showcase. The slide presentation addresses Aerie's proprietary PRINT® drug delivery platform and retina product candidates AR-1105 (dexamethasone implant, Phase 3 ready), AR-13503 (Rho kinase/Protein kinase C inhibitor implant, Phase 2a), and AR-14034 (pan-VEGF receptor inhibitor implant, preclinical).

The slide presentation from today's event is available now and may be accessed by visiting Aerie's website at http://investors.aeriepharma.com.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa®, including the product label, is available at www.rhopressa.com. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan®, including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for the treatment of dry eye disease, wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.


These press releases may also interest you

at 10:20
Members of the media are invited to attend an important event regarding a biomanufacturing announcement to help address the fight against COVID-19. Government officials and industry leaders will be coming together on Monday, December 6, at 9:30 a.m....

at 09:30
During the forecast period, the Protein Assays industry will see an increase in spending of around USD 1.06 Billion. However, the majority of this expansion will be driven by only a few regions. Furthermore, due to their supplier base, North America,...

at 08:00
Kazia Therapeutics Limited , an oncology-focused drug development company, is pleased to announce positive final data from a phase II clinical study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298). The results confirm...

at 00:10
Summary Brand(s): Great Value Product: Chicken Burgers Companies: Belmont Meat Products Ltd. Issue: Food ? Allergen ? Egg Category: Meat and poultry (Frozen) What to do: If you have an allergy to egg, do not consume the recalled product Audience:...

3 déc 2021
Alberta pharmacists hit yet another milestone this past week, having now administered over 3.3 million COVID-19 vaccines, which makes them the single largest provider of COVID-19 vaccine in the province....

3 déc 2021
The medical packaging films market is fragmented. Vendors are using various organic and inorganic growth strategies to compete in the market. The market is expected to grow by USD 2.02 bn from 2021 to 2026, progressing at a CAGR of 5.23%....



News published on 7 october 2021 at 16:05 and distributed by: